CRISPR-Cas9: A method for establishing rat models of drug metabolism and pharmacokinetics

Jian Lu a,b,† Jie Liu a,b,† Yuanqing Guo a,† Yuanjin Zhang a, Yeye Xu a, Xin Wang a,b *

a Changning Maternity and Infant Health Hospital, East China Normal University, Shanghai 200051, China
b Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China

Received 23 September 2020; received in revised form 25 October 2020; accepted 16 November 2020

KEY WORDS
CRISPR-Cas9; Drug metabolism; Pharmacokinetics; Animal model; Gene editing

Abstract The 2020 Nobel Prize in Chemistry recognized CRISPR-Cas9, a super-selective and precise gene editing tool. CRISPR-Cas9 has an obvious advantage in editing multiple genes in the same cell, and presents great potential in disease treatment and animal model construction. In recent years, CRISPR-Cas9 has been used to establish a series of rat models of drug metabolism and pharmacokinetics (DMPK), such as Cyp, Abcb1, Oatp1b2 gene knockout rats. These new rat models are not only widely used in the study of drug metabolism, chemical toxicity, and carcinogenicity, but also promote the study of DMPK related mechanism, and further strengthen the relationship between drug metabolism and pharmacology/toxicology. This review systematically introduces the advantages and disadvantages of CRISPR-Cas9, summarizes the methods of establishing DMPK rat models, discusses the main challenges in this field, and proposes strategies to overcome these problems.

Abbreviations: AAV, adeno-associated virus; ADMET, absorption, distribution, metabolism, excretion and toxicity; BSEP, bile salt export pump; CRISPR-Cas, clustered regularly interspaced short palindromic repeats-CRISPR-associated; crRNAs, CRISPR RNAs; DDI, drug—drug interaction; DMPK, drug metabolism and pharmacokinetics; DSB, double-strand break; HBV, hepatitis B virus; HDR, homology directed repair; HIV, human immunodeficiency virus; HPV, human papillomaviruses; KO, knockout; NCBI, National Center for Biotechnology Information; NHEJ, non-homologous end joining; PAM, protospacer-associated motif; pre-crRNA, pre-CRISPR RNA; RNP, ribonucleoprotein; SD, Sprague-Dawley; sgRNA, single guide RNA; SREBP-2, sterol regulatory element-binding protein 2; TALE, transcriptional activator-like effector; TALEN, transcriptional activators like effector nucleases; tracRNA, trans-activating crRNA; T7E1, T7 endonuclease I; OATP1B, organic anion transporting polypeptides 1B; OTS, off-target site; WT, wild-type; ZFN, zinc finger nucleases.

*Corresponding author. Tel.: +86 21 2420 6564; fax: +86 21 5434 4922.
E-mail addresses: xwang@bio.ecnu.edu.cn, uxinwang@gmail.com (Xin Wang).
† These authors made equal contributions to this work.

Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2021.01.007
2211-3835 © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Clustered regularly interspaced short palindromic repeats (CRISPR)-associated (CRISPR-Cas) system is an adaptive immune system existing in bacteria and archaea. CRISPR-Cas9 technology is the third-generation artificial nuclease technology based on the CRISPR-Cas system, and has become a powerful gene editing tool. In particular, the 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer A. Doudna for their development of the CRISPR-Cas9 for genome editing. CRISPR-Cas9 technology is widely used in the construction of gene editing models both in vitro and in vivo. In recent years, scientists have constructed and reported a series of gene-edited animal models for the drug metabolism and pharmacokinetics (DMPK) research based on this technology. These models provide excellent tools for the study of drug metabolism and gene functions in vivo.

The aim of this review is not only to introduce the basic information of CRISPR-Cas9 technology, but also to discuss the difficulties and challenges of this technology in the construction of ADME-related animal models. Thus, this review firstly introduces the basic information of CRISPR-Cas system and technology, and then compares the advantages and disadvantages of CRISPR-Cas9 with other artificial nuclease technologies. Furthermore, we describe the application of CRISPR-Cas9 technology in the construction of animal models, especially in the generation of DMPK-related animal models. Finally, taking the DMPK animal model as an example, this review summarizes the basic steps of constructing a gene-edited animal model based on CRISPR-Cas9 technology. At the same time, difficulties and challenges in model construction are pointed out, and the corresponding solutions are also proposed.

2. Basic information of CRISPR-Cas9 system

2.1. CRISPR-Cas system

CRISPR-Cas adaptive immune system is a natural defense system adopted by bacteria and archaea to defend against phage infection. It provides microbes with RNA-guided adaptive immunity to foreign genetic elements by guiding nucleases binding and cleaving specific nucleic acid sequences. The discovery of this excellent system has completely changed modern molecular biology. Now it has been engineered as an RNA-guided endonuclease system for genome editing, providing an incredible tool for the treatment of genetic diseases. It introduces desirable engineering genetic characteristics, including live cell imaging, functional gene high-throughput screening and nursing diagnosis.

These systems consist of two key components. One is a genomic locus called CRISPR array, which contains a series of short sequences of foreign DNAs called spacers. These spacers enable recognition of specific mobile genetic elements encountered previously. The spacer region is separated by some repetitive regulatory sequences, named repeats. These spacers, together with repeats and the leader sequence (AT-rich), constitute the CRISPR array. When infected by a new phage, the CRISPR array is expanded by adding a new spacer from the phage genome. Further, the invading foreign DNA can be recognized and inserted into a genome locus to form CRISPR region. The other key component of CRISPR-Cas systems is Cas protein, which is encoded by Cas genes on both sides of the CRISPR arrays.

As shown in Fig. 1, CRISPR-Cas system can be divided into six types according to different “signature genes”, and additionally distinguished into two classes based on the structure of the “effector complex”. Class I ribonuclease protein (RNP) consists of multiple subunits, while class 2 system consists of a single unit RNP complex. Each class includes three types. Types I, III, and IV systems are included into class 1 system, and types II, V, VI systems are grouped into class 2 system. Types I–III systems are distinguished with the differences of signature proteins: Cas3 for type I, Cas9 for type II and Cas10 for type III. Different from the above systems, type IV system has Cas1, an uncharacterized protein. Type V system also contains a Cas9-like single nuclease, either Cpf1, C2c1, or C2c3, depending on the subtype, and type VI system has C2c2. Finally, according to additional signature genes and characteristic gene arrangement, each type is divided into multiple subtypes. Type I contains subtypes A–F and U. Type III contains subtypes A–D. Type II contains subtypes A–C. Type V contains subtypes A, B and U. Type VI contains subtypes A–C.

The immune mechanism of CRISPR includes three stages: adaption, maturation and interference. During the adaption phase, foreign genome elements are recognized, acquired, and integrated into the CRISPR array as a new spacer. The maturation phase includes the transcription of CRISPR array, which contributes to the formation of pre-CRISPR RNA (pre-crRNA). And the pre-crRNA is further processed into mature CRISPR RNAs (crRNAs), each of which contains a single spacer. Subsequently, crRNAs are incorporated into RNP complexes as effector complexes along with Cas proteins. This effector complex recognizes the nucleic acid encoded by crRNA, and then triggers the interference stage, resulting in the degradation of the recognized nucleic acid complementary to the crRNA spacer sequence. These steps are performed by Cas proteins.

2.2. CRISPR-Cas9 technology

CRISPR-Cas9 is a type II CRISPR-Cas system, which has been developed into a gene editing technology. The technology involves two key components: single guide RNA (sgRNA) matching the target gene and Cas9 protein causing double strand DNA break. Two components are necessary for the sgRNA: a target specific crRNA and a trans-activating crRNA (tracRNA). These two parts work together to guide Cas9 protein to bind to specific genomic sites through the principle of complementary base pairing between crRNA sequence and target sequence.

After binding to the crRNA/tracRNA duplex, Cas9 begins to bind and scan the foreign DNA containing the protospacer-associated motif (PAM) located at the 5’ end of the protospacer sequence, where Cas9 protein binds and mediates a specific double-strand break (DSB). The PAM consists of a canonical
NGG or NAG sequence\textsuperscript{22}. The DNA strand is then unwound, allowing sgRNA to perform complementary verification. A DSB is produced by positive recognition and can be repaired by either non-homologous end joining (NHEJ), typically leading to random insertion/deletion, or by homology directed repair (HDR), in which the homologous section of DNA is used as a repair template\textsuperscript{22}.

As a reliable and adaptable tool, CRISPR-Cas9 system has greatly accelerated the pace of research and has been applied in a wide range of fields. Because of its practicability, simplicity and efficiency\textsuperscript{23}, it has been engineered for genome editing, and then applied to the establishment of animal models, screening of functional genomes and correction of genetic disorders\textsuperscript{19}. It is worth noting that with the deepening understanding of CRISPR component transmission, more opportunities in the CRISPR-Cas9 genome editing \textit{in vivo} will appear. Therefore, CRISPR-Cas9 has developed into a general technical tool for gene editing, especially for genome editing \textit{in vivo} to generate powerful animal models.

### 2.3. Advantages and disadvantages of CRISPR-Cas9 technology

Artificial nuclease is a revolutionary improvement in biological research, including zinc finger nucleases (ZFN), transcriptional activators like effector nucleases (TALEN) and CRISPR (Table 1). In fact, these emerging technologies have greatly expanded the ability to generate animal models, which are used in disease research and DMPK.

| Characteristics | ZFN | TALEN | CRISPR |
|-----------------|-----|-------|--------|
| Components      | DNA binding and cleavage domain | TALE protein | sgRNA |
| Recognition sites | (9–18 bp)*2 | DNA cleavage domain | DNA binding domain |
| Disadvantages   | High cost | Cytotoxicity | (8–31 bp)*2 |
|                 | Cytotoxicity | Large size | Cytotoxicity |
|                 | Cumbersome operation | Prokaryotic origin | Large size |
| Advantages      | Simple design | High success rate | High efficiency |
|                 | High specificity | Design flexibility | Easy construction |

In 2009, the first knockout (KO) rat was reported by using ZFN\textsuperscript{24}. ZFN consists of two functional components: the DNA binding domain of zinc-finger protein and the DNA cleavage domain of Fok I endonuclease. ZFN works in dimetric form, and its target site size is (9–18 bp)*2. The zinc-finger protein region includes three to six Cys2–His2 fingers, which recognize a tripeptide nucleotide code. After recognizing the binding site, it dimerizes and activates Fok I endonuclease, and then cleaves DNA\textsuperscript{25,27}.

Similar to ZFN, TALEN consists of two parts: transcriptional activator-like effector (TALE) protein and DNA cleavage domain. The TALEN is a modular DNA recognition code secreted by the plant pathogenic bacteria genus Xanthomonas, which can identify a target with (8–31 bp)*2. And TALE protein contains DNA-binding domains composed of repeated 33–35 amino acid sequence\textsuperscript{26,28}. Just like ZFN, the DNA cleavage of TALEN is coupled to the nonspecific nuclease Fok I. As mentioned above, CRISPR-Cas9 system contains two key components: sgRNA and Cas9 protein, enabling it to recognize targets with a size of 20 bp+NGG*1.

ZFN, TALEN and CRISPR-Cas9, as genome editing tools, have great potential in biomedical research. However, there are still many challenges to be addressed in these three technologies. One of the main challenges is the specificity of gene editing methods. Thus, it is necessary to study new methods to control off-target effects. In addition, the existing delivery methods should be optimized to achieve an adequate level of efficiency\textsuperscript{23}. Although ZFN is special, it needs highly skilled experts along with screening of ZFN library to engineer it, while TALEN is...
easier to construct. However, compared with ZFN, TALEN has the disadvantages of large size, prokaryotic origin, and cytotoxicity. The large size of TALEN may limit its delivery through size-restricted vectors such as adeno-associated virus (AAV), which has been shown to be adaptive to ZFN genes. At the same time, TALEN is a complicacy system due to its repetitive sequences, which leads to its complex delivery system and structure. CRISPR-Cas9 is a simplified genome editing tool, which has aroused the interest of the scientific community. Its main advantage is that it works through Waston-Crick base-pairing between sgRNA and target DNA. Unlike ZFN and TALEN technologies, CRISPR does not rely on protein engineering. Furthermore, CRISPR-Cas9 is simple and efficient. It only needs to synthesize a small fragment of RNA to recognize the target. Technical characteristics of three kinds of artificial nuclease are summarized in Table 1. In short, all these systems have some shortcomings, but the comparison with the other two systems highlights the characteristics of CRISPR-Cas9. Therefore, CRISPR-Cas9 system is a feasible genome editing method, and has been widely used in animal model construction.

3. Application of CRISPR-Cas9 technology in animal model generation

3.1. Animal models for disease research

One of the most exciting applications of CRISPR-Cas9 is the generation of animal models for the study of a variety of diseases. Direct injection of Cas9 mRNA and sgRNA for gene editing of single cell embryos is a new method for rapid establishment of animal models. This approach has been successfully applied to the generation of animal models, such as mice, rats, monkeys, zebrafish and cattle. In particular, transgenic animals can be changed more easily, faster and more efficiently. These animal models may be important in vivo models for diseases, such as cancer, bone disease, immunodeficiency disease and many other inherited human diseases. A good example in the establishment of animal models for tumor research was done on lung cancer by establishing a Cre-dependent Cas9 knock in mice. A prominent example in the study of cardiovascular disease is the generation of transgenic mice with severe heart failure by using AAV9 to transfer sgRNA targeting Myh6 locus of cardiomyopathy. Furthermore, CRISPR-Cas9 system has also been used to establish animal models of infectious disease like human immunodeficiency virus (HIV), human papillomaviruses (HPV), and chronic hepatitis B virus (HBV).

3.2. Animal models for DMPK research

Apart from disease models, CRISPR-Cas9 system is also widely used for the generation of DMPK-related animal models. DMPK mainly studies the absorption, distribution, metabolism, excretion and toxicity (ADMET) of drugs. It is necessary to understand the properties of ADMET for drug discovery and development. The CRISPR-Cas9 system, as a powerful genetic engineering tool, provides an effective method for DMPK research. Currently, the animal models for drug metabolizing enzyme mainly focus on CYP enzymes. These models are mainly based on Sprague-Dawley (SD) or Wistar rats, and the targeted genes code proteins in CYP families 1, 2 and 3, such as CYP2C11, CYP2E1, CYP2J2, CYP3A1/2. Therefore, these models are grouped as CYP1, CYP2 and CYP3. We have reported the first CRISPR-Cas9 mediated gene KO rat model of Cyp2e1. Then, the Cyp3a1/2 double KO rat model is also generated by CRISPR-Cas9 system. The in vitro (substrate: midazolam and nifedipine) and in vivo (substrate: nifedipine) metabolism studies of Cyp3a1/2 demonstrated the functionally inactivity of Cyp3a1/2 in KO rats, which provided a powerful tool for the study of ADMET. Moreover, we investigated the potential effect of CYP3A on the pharmacokinetic interaction between erlotinib and docetaxel using Cyp3a1/2 double KO rat model. Our data suggest that CYP3A is a key factor in docetaxel inhibiting erlotinib biotransformation in vitro and in vivo in rats. It is also concluded that Cyp KO rat model is a powerful animal model for studying DDI. In 2018, the Cyp2c11-null rat model was also successfully generated by using the CRISPR-Cas9 method. Using tolbutamide as probe substrate, the metabolic function of CYP2C in KO rats was detected, but there was no significant difference between WT and KO rats. In the further study, this Cyp2c11-null rat model was used to explore not only the effects of CYP2C11 on the pharmacokinetics and pharmacodynamics of warfarin, but also the effects of CYP2C11 on vasorelaxation in vivo.

3.2.1. Animal models for drug metabolizing enzyme research

Currently, the animal models for drug metabolizing enzyme mainly focus on CYP enzymes. These models are mainly based on Sprague-Dawley (SD) or Wistar rats, and the targeted genes code proteins in CYP families 1, 2 and 3, such as CYP2C11, CYP2E1, CYP2J2, CYP3A1/2. We have reported the first CRISPR-Cas9 mediated gene KO rat model of Cyp2e1. Then, the Cyp3a1/2 double KO rat model is also generated by CRISPR-Cas9 system. The in vitro (substrate: midazolam and nifedipine) and in vivo (substrate: nifedipine) metabolism studies of Cyp3a1/2 demonstrated the functionally inactivity of Cyp3a1/2 in KO rats, which provided a powerful tool for the study of ADMET. Moreover, we investigated the potential effect of CYP3A on the pharmacokinetic interaction between erlotinib and docetaxel using Cyp3a1/2 double KO rat model. Our data suggest that CYP3A is a key factor in docetaxel inhibiting erlotinib biotransformation in vitro and in vivo in rats. It is also concluded that Cyp KO rat model is a powerful animal model for studying DDI. In 2018, the Cyp2c11-null rat model was also successfully generated by using the CRISPR-Cas9 method. Using tolbutamide as probe substrate, the metabolic function of CYP2C in KO rats was detected, but there was no significant difference between WT and KO rats. In the further study, this Cyp2c11-null rat model was used to explore not only the effects of CYP2C11 on the pharmacokinetics and pharmacodynamics of warfarin, but also the effects of CYP2C11 on vasorelaxation in vivo.

3.2.2. Animal models for drug transporter research

Drug transporter KO model is a useful tool to study the pharmacokinetics based on DDI. It has been reported that quizartinib (a second-generation FLT3 inhibitor) is transported through multidrug efflux transporters, such as ABCB1 and ABCC2, by using Abcb1a/b−/−, Abcb1a/b and Abcg2−/− mice. It provides a possible rationale for using ABCB1/ABCG2 inhibitors together with quizartinib to increase its concentration in the brain to treat malignant lesions situated behind the blood–brain barrier. To date, the research on gene editing of drug transporters by CRISPR-Cas9 has focused on the ATP-binding cassette transporters. A Madin-Darby canine kidney II cell line was established in vitro by using CRISPR-Cas9 to knock out endogenous canine MDR1. And various in vivo transporter models for ADMET studies have also been developed by using CRISPR-Cas9 system. These models allow the study of the role of specific drug transporters in DMPK.

| Table 2 DMPK-related rat models generated by using CRISPR-Cas9. |
|---------------------|---------------------|---------------------|---------------------|
| Gene               | Strain              | Modification        | Year               |
| Cyp2e1             | SD rats             | KO                  | 2016               |
| Cyp2e1/2/3/4/5     | Wistar rats         | KO and CYP2D6 knock in | 2016               |
| Cyp3a1/2           | SD rats             | KO                  | 2017               |
| Cyp2c11            | SD rats             | KO                  | 2018               |
| Cyp2j3/10          | SD rats             | KO                  | 2020               |
| Drug transporter   | Abcb1a/b            | SD rats             | 2019               |
| Slco1b2            | SD rats             | KO                  | 2020               |

2976 Jian Lu et al.
research. For example, we generated a novel Abcb1 (Abcb1a/b)
double KO rat model by the CRISPR-Cas9 system, which can
be used as a powerful tool to study the function of MDR1 in
drug absorption, tumor multidrug resistance and drug target
validation. In addition, the Slco1b2 KO rat model was also
successfully constructed by CRISPR-Cas9 technology. We
further applied this model to explore the role of organic anion
transporting polypeptides 1B (OATP1B) in the interaction be-
tween paclitaxel and sorafenib.

3.3. Animal models for physiological function research of
DMPK genes

3.3.1. Animal models for physiological function research of
CYP isoforms

CYP isoforms (CYPs) play an important role in chemical meta-
bolism, toxicity, and carcinogenicity. Most drugs are inactivated
by CYPs, either directly or by promoting excretion from the body.
At the same time, various endogenous substances are bioactivated
by CYPs to form active compounds. Therefore, the loss of CYPs
has a profound impact on the metabolism and physiological functions
of some endogenous substances. Now, the CYP KO animal models established by CRISPR-Cas9 have been a powerful
tool to study the physiological function of CYPs. Members of
the CYP3A subfamily are the most abundant CYP enzymes both in
the liver and small intestine. Cyp3a KO (Cyp3a KO) mice were
used to investigate the effects of CYP3A deficiency on gene
expression responsible for cholesterol influx, efflux, metabolism,
and biosynthesis. Compared with wild-type (WT) mice, Cyp3a KO
mice had higher mRNA levels of cholesterol biosynthesis and bile
acid synthesis related enzyme genes, higher nuclear levels of sterol
regulatory element-binding protein 2 (SREBP-2), and lower liver
cholesterol levels. These results suggest that decrease of hepatic
total cholesterol in Cyp3a KO mice may be the result of increased
bile acid synthesis. However, the concentrations of cholesterol and
bile acids in Cyp3a KO rat model (generated by CRISPR-Cas9) did not change significantly. This may reflect the species differences in the
metabolism of cholesterol and bile acids mediated by CYP3A. As a
powerful tool, Cyp3a KO mice have also been used to study the
relationship between CYP3A and testosterone in the prostate. The
subsequent study reported a significant increase in plasma free
testosterone levels in Cyp3a KO mice and a decrease in the activity
of testosterone 6β-hydroxylation in liver microsomes. Based on
remarkably increased mRNA expression levels of the AR target
genes and more abundant AR bindings to the promoter region in the
prostate, Cyp3a deficiency promotes Scar expression by activating
AR. The increase of testosterone was also observed in Cyp3a KO rats.
However, the mechanism and role of elevated testosterone need
to be further explored. Interestingly, the number of sperm in testis
of Cyp2c11 KO rats decreased and puberty was delayed for 20 days,
demonstrating that CYP2C11 is related to the hydroxylation of testos-
erone and prostaglandin. In addition, CYP2C11 also plays an
important role in the regulation of blood pressure mediated by
epoxyeicosatrienoic acid.

3.3.2. Animal models for physiological function research of
drug transporters

Drug transporters, which allow drugs to enter and leave cells
through carrier-mediated pathways, are now considered to be an
important determinant of some endogenous substance. With the
rapid development of CRISPR-Cas9 gene editing technology,
animal models of drug transporter gene deletion have been
generated and applied to the study of physiology and pathology.
OATP is an important family for pharmacokinetics formed by
influx transporters expressed in different tissues. In Oatp1a1b
and Abcc3 deficient mice, ABCB3 secretes bilirubin conjugates
into the blood, and the OATP1A1/IB transporter mediates liver
resorption. In the contrast, the Oatp1b2 KO rats generated by
CRISPR-Cas9 show the phenotypes of Rotor syndrome and
hyperbilirubinemia, and show the characteristic of significantly
increased bilirubin concentration in blood. Therefore, the
Slco1b2 KO rat model may be an important disease model for the
study of Rotor syndrome, hyperbilirubinemia, and some
hyperbilirubinemia-related diseases.

CRISPR-Cas9 gene editing of drug transporters has also focused on ATP-binding cassette transporter family, where it has
been applied in the KO of Abcc1 homologs in the zebrafish and
rat. Applied CRISPR-Cas9 genome editing technology to delete Abcc1b in zebrafish and found that these mutants
died prematurely. By histological and ultrastructural analyses, they also found that hepatocytes of Abcc1b KO
zebrafish failed to excrete bile acid with fluorescent tag, which is a
substrate of human bile salt export pump (BSEP). We used
CRISPR-Cas9 system to construct Abcc1b KO rats, and found
the serum levels of direct bilirubin, indirect bilirubin, total bili-
rubin, HDL-cholesterol, total cholesterol, and total bile acid were
significantly increased in KO rats. In addition, the expression of
Abcg5 and Abcg8 in the liver of KO rats was significantly lower
than that in WT rats, indicating that cholesterol and bile acid may
be deposited in the body, and bilirubin may be the endogenous
substrate of MDR.

4. Challenges of CRISPR-Cas9 animal model construction:
A case study of DMPK model

Although the CRISPR-Cas9 system is widely used in the con-
struction of gene editing animal models, there are still some
problems worthy of attention. In this part, we will briefly intro-
duce the general process of CRISPR-Cas9 mediated gene KO. The
flowchart of gene editing animal model construction based on
CRISPR-Cas technology is summarized in Fig. 2. In addition, this
part will take the DMPK model construction as an example to
illustrate the challenges in the model construction.

4.1. Target sites prediction and selection

The gene sequence is obtained from the National Center for
Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.gov/ pubmed). According to the annotation (under the format of ‘Gene
Bank’) of the gene, the cDNA sequence can be obtained. The
“CRISPR DESIGN” online system (http://crispr.mit.edu/) can
predict potential target sites by submitting the cDNA sequence of
the gene. Here are some tips for target selection. First, in order to
knock out the gene of interest more completely, the target site is
preferably selected in the exon near the start codon. For example,
target sites for the KO of Cyp3a1 and Cyp3a2 in rats are selected
in the second exon, which are just downstream to the initiation
codon. If the exon near the start codon is too short to find a
suitable target site, the target site can be searched downstream.
For the targeting of Abcb1a and Abcb1b, the target is selected on
the third exon because the first two exons are less than 70 bp.
Second, in order to improve the targeting efficiency, multiple target sites can be designed for the same gene of interest.

4.2. Construction of sgRNA in vitro

RNA injection method is chosen to generate double DNA strain breaks. To synthesize the sgRNA \textit{in vitro}, the T7 \textit{in vitro} Transcription Kit was employed. The procedure is summarized as follows:

i. Single-stranded DNA (60 bp) containing T7 promoter sequence, the target site sequence (18 bp) and partial sequence homologous to the sgRNA backbone, successively from 5' end to 3' end, was synthesized.

ii. The single-stranded DNA and sgRNA backbone were spliced by overlap PCR to form the sgRNA transcription precursor corresponding to the target.

iii. The transcription products of sgRNA were synthesized from its precursor by using the T7 \textit{in vitro} Transcription kit.

iv. The sgRNA was purified by RNA purification kit, and then stored at \(-80^\circ\text{C}\) after being tested by agarose gel electrophoresis.

4.3. Construction of Cas9 mRNA in vitro

The Cas9 expression vector is available on the market. To synthesize Cas9 mRNA \textit{in vitro}, the Sp6 \textit{in vitro} transcription kit can be used. The procedure is summarized as follows:

i. The expression vector of Cas9 was linearized by endonuclease and purified by phenol chloroform extraction.

ii. Using the linearized plasmid as a template, Cas9 mRNA was transcribed through Sp6 \textit{in vitro} transcription kit.

iii. The Cas9 mRNA was purified by RNA purification kit, and then stored at \(-80^\circ\text{C}\) for further use, after being tested by agarose gel electrophoresis.

4.4. Co-microinjection of sgRNA and Cas9 mRNA into zygotes

The sgRNA and Cas9 mRNA need to be delivered into cytoplasm of the zygotes to perform their gene editing function. Therefore, co-microinjection technology is used to achieve this purpose. The general steps of co-microinjection are summarized as follows:

i. Superovulation induction. Eight-week-old female rats were intraperitoneally injected with horse pregnant serum gonadotropin and human chorionic gonadotropin to induce superovulation.

ii. Mating. The super ovulated female rats mated with normal male rats to form fertilized eggs.

iii. Obtaining fertilized eggs. Female rats with vaginal suppository (indicating successful mating) were euthanized. The fertilized eggs were removed from the fallopian tubes, placed in the medium and incubated at 37 \(^\circ\text{C}\) for 2 h.

iv. Microinjection. The sgRNA and Cas9 mRNA were mixed and co-injected into the fertilized eggs by microinjector.
v. Pseudo-pregnant rat preparation. Male rats ligated the fallopian tubes, and then mated with female rats to generate the pseudo-pregnant rat. On the next day, the vaginal suppository was checked. The detection of vaginal suppository indicated the pseudo-pregnant rats were successfully prepared.

vi. Fertilized eggs transfer. The surviving fertilized eggs were transplanted into the oviduct of the female pseudo-pregnant rats for natural implantation and development.

Both Cas9 mRNA and Cas9 protein can be injected into zygote, and each method has its own advantages and disadvantages. For Cas9 sgRNA, the preparation process is relatively simple, while the relatively long-term transcription activity of sgRNA may increase the risk of off-target effects. For Cas9 protein, it can work directly as a functional protein without the need for transcription, and the short half-life may reduce the possibility of off-target occurrence. However, the synthesis of Cas9 protein in vitro is relatively complex and the experimental period is long.

4.5. Genotyping of founders and progenies

T7 endonuclease I (T7E I) assay can be applied for the genotyping of F0 chimeras preliminarily. The genomic DNA of founders is usually extracted from the toes of newborn rats with a standard extraction procedure. The DNA sequences flanking the target site should be amplified for genotyping of founders and progenies. An anneal program can be conducted with PCR products to generate mismatched heteroduplexed DNA. Then resulting products were digested with T7E I for 30 min, and detected by agarose gel electrophoresis. If T7EI digestion produces a small band, it indicates that the offspring may have a gene editing at the target site.

To identify the modification details of F0 founders, PCR products amplified from each rat toe genome can be cloned into pMD-18T vectors according to the instructions of TA cloning kit. Then the precise sequence around the target site can be obtained by gene sequencing. For the genotyping of F1 or F2 progenies, PCR products can be directly sequenced.

4.6. Off-target site validation

Target-sites can be submitted to the Cas9 online designer (http://cas9.wicp.net/), which contains a genome-wide sgRNA off-target searching tool. Off-target site (OTS) with relatively high score should be selected for further PCR analysis. The off-target effects should be evaluated by T7E I digestion or gene sequencing. Furthermore, to evaluate off-target effects more comprehensively, the deep sequencing is generally used.

4.7. Expression detection of target gene

In order to further confirm the success of gene deletion, it is necessary to detect the mRNA and protein expression levels of the target gene in KO rats. In general, the mRNA level of target gene is detected by Q-PCR or agarose gel electrophoresis. The protein level of target gene is usually measured by Western blot or immunohistochemical analysis.

In order to verify whether the knocked-out gene will produce a truncated protein, it is better to use an antibody that specifically recognizes the N-terminus of the protein for protein expression analysis. However, this may be limited by commercial antibodies. In some cases, the protein band or spot may also be detected in the KO model. For example, we have reported a Cyp3a1/2 double KO rat model, but the CYP3A band can be detected in the liver tissue of KO rats by Western blot analysis. This may be because the antibody used for protein detection can recognize the truncated protein produced by the deleted gene. In addition, it may be due to the existence of homologous subtypes, which has a similar sequence to the target gene, and the antibody used can also recognize this homologous subtype. To solve this problem, it is necessary to develop and prepare more specific antibodies. With these customized antibodies, some specific isofrom or region (such as C-terminus) of the target gene can be detected.

4.8. Function evaluation

The method of function evaluation depends on the role of the KO gene. For DMPK-related genes, their functions mainly include drug metabolism and transport. CYP is an important phase I drug metabolizing enzyme, and the probe substrates are generally used to verify the function of KO animal model. For example, nifedipine and chloroxazone are used to detect the metabolic function of Cyp3a1/2 and Cyp2e1 KO rats in vitro and in vivo, respectively. Although gene KO can significantly reduce the metabolism of probe substrate, it does not mean that the substrate is not metabolized in KO rats. Sometimes gene KO may not change the metabolism of certain probe substrates. The main reason is that the so-called probe substrate may be metabolized by other enzymes at the same time. Therefore, different substrates should be selected to verify the function of KO model.

4.9. Compensatory changes in the expression of other ADME related genes

To explore whether the deletion of one gene will lead to the expression changes of other ADME related genes, the compensatory expression of other specific proteins can be measured. The ADME related proteins to be detected include absorption transporters (such as OATP1B2), efflux transporters (such as MDR1), phase I enzymes (such as CYP) and phase II enzymes (such as UGT). The compensatory changes can be measured at the mRNA level, while it is better to perform compensatory expression testing at the protein level if commercial antibodies are available or easy to be prepared. KO of the ADME gene may lead to the change of genes with similar or opposite functions. These changes need to be considered in the subsequent experimental design and results analysis. In addition to expression, the most direct way to verify compensation is to detect the function of compensated genes, which is generally applicable to genes with expression compensation.

4.10. Physiological and pathological evaluation

More and more studies have found that ADME related genes not only participate in the clinical drug disposition, but also participate in the disposition of many endogenous substances. The latter may affect the concentration of endogenous substances, thereby changing the physiological or pathological state of the body. Therefore, it makes sense to evaluate the physiological and pathological changes of the KO rat. The methods to study the
physiological and pathological changes of KO rats generally include the detection of blood biochemical index, tissue and organ sections and staining. Furthermore, other tests related to the potential function of KO genes can also be used to further improve the assessment of the physiology and pathology of KO animals. For example, the testosterone concentration of CYP3A KO model and the cholesterol concentration of the Abcb1 KO model should be included in physiological and pathological evaluation. In addition, the physiological and pathological evaluation of KO animal model can not only fully characterize the animal model, but also discover the new functions of ADME related genes.

5. Expectations

Due to its simplicity and ease of use in genome editing, CRISPR-Cas9 has been widely used in animal construction. In order to improve the efficiency and accuracy of the system, various strategies have been explored to increase the delivery efficiency and reduce the off-target effect. The introduction of Cas9 protein into nucleus is a major obstacle to the application of CRISPR-Cas9. It can be delivered in a variety of formats, including viral/plasmid-based approaches, Cas9-encoded RNA and direct Cas9 protein delivery. In the future, some novel CRISPR delivery methods may be explored to improve the delivery efficiency. In fact, the off-target effect is an unavoidable issue of CRISPR-Cas9 mediated gene targeting technology. The off-target problem of CRISPR-Cas9 system not only affects its application in clinical gene therapy, but also affects the construction of experimental animal models to a certain extent. With the development of off-target detection technology (including deep sequencing, GUIDE-seq and BLESS), the off-target effect of the CRISPR-Cas9 system will be evaluated more comprehensively. Various approaches have been taken to reduce off-target mutations, including SpCas9-HF1, a highly-fidelity variant harboring alterations designed to reduce non-specific DNA contacts. In addition, the discovery of new Cas genes that can recognize different PAM sequences may be a potential solution to the off-target problem. Despite these limitations, CRISPR can cut the time and cost of making new animal models by one-third, thus putting tailor-made models within reach of a wide range of researchers. With the increase of success rate and efficiency of exogenous gene expression. In particular, it is a challenging task to introduce large gene segments (\(>5 \text{ kb}\) in length) into the human genome, which is often desired for humanization. Therefore, it is a promising research direction to explore the effective construction of ADME-related gene humanized rat model.

Although CRISPR-Cas9 technology is widely used in the construction of ADME-related animal models, there is still much more in-depth work to be done. DMPK-related gene editing animal models can be extensively used in the study of metabolism, transport and toxicity of drugs or compounds, and can also be used to explore the mechanism of DDI. Moreover, the physiological and pathological functions of DMPK-related genes are still an important research direction. With the further study of DMPK-related gene editing animal models, we believe that more abundant animal model types, such as humanized model, will be generated and reported. At the same time, more influential achievements will appear in the field of drug metabolism and pharmacokinetics.

Acknowledgments

This work was supported in part by grants from the National Natural Science Foundation of China (No. 81773808) and the Science and Technology Commission of Shanghai Municipality (Nos. 17140901000, 17140901001 and 18430760400, China).

Author contributions

Xin Wang was responsible for the conception and design of the review. Jian Lu, Jie Liu and Yeye Xu collected literatures. Jian Lu, Jie Liu and Yuanqing Guo analyzed literatures and summarized results. Jian Lu and Jie Liu drafted the manuscript. Yuanjin Zhang and Xin Wang revised the manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Karlsgren M, Simoff I, Keiser M, Oswald S, Artursson P. CRISPR-Cas9: a new addition to the drug metabolism and disposition tool box. Drug Metab Dispos 2018;46:1776–86.
2. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 2010;8:317–27.
3. Makarova KS, Koonin EV. Annotation and classification of CRISPR-Cas systems. Methods Mol Biol 2015;1311:47–75.
4. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science 2018;361:866–9.
Gene editing DMPK rat models by CRISPR-Cas9

5. Stern A, Keren L, Wurtzel O, Amitai G, Sorek R. Self-targeting by CRISPR: gene regulation or autoimmunity?. Trends Genet 2010;26:335–40.

6. Vercoe RB, Chang JT, Dy RL, Taylor C, Gristwood T, Clulow JS, et al. Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands. PLoS Genet 2013;9:e1003454.

7. Jansen R, Embden JD, Gaastera W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 2002;43:1565–75.

8. Kunin V, Smargorina A, Scott D, Cox D, Pyzocha N, Yan W, et al. Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol 2011;15:169–82.

9. Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. Nat Rev Mol Cell Biol 2013;14:297–308.

10. Ishino Y, Krupovic M, Forterre P. History of CRISPR-Cas systems and their applications. Int J Mol Sci 2020;21:1122.

11. Wright AV, Nunez JK, Doudna JA. Biology and applications of CRISPR-Cas systems and their applications. Curr Opin Microbiol 2018;44:82.

12. Koonin EV, Makarova KS, Zhang F. Diversity, classification and evolutionary conservation of CRISPR-Cas systems and their applications. Curr Opin Biotechnol 2014;27:46–51.

13. Zarnago JP, Matesanz E, Sanz J, Escribano E, Vila C, et al. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc Natl Acad Sci U S A 2016;113:338–43.

14. Zarnago JP, Matesanz E, Sanz J, Escribano E, Vila C, et al. CRISPR/Cas9 nuclease-mediated gene knock-in in bovine-induced pluripotent cells. Stem Cells Dev 2015;24:393–402.

15. Estrada D, Rios Costa N, da Costa RG, Medeiros R. CRISPR-Cas9 therapies in experimental mouse models of cancer. Future Oncol 2018;14:2083–95.

16. Platt RJ, Chen S, Zhou Y, Iyin JM, Swiech L, Kempont HR, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014;159:440–55.

17. Carroll KJ, Makarewich CA, McNally J, Anderson DM, Zentilin L, Liu N, et al. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc Natl Acad Sci U S A 2016;113:338–43.

18. Zhou S, Hua L, Takahashi Y, Narita S, Liu YH, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun 2014;450:1422–6.

19. Yoshida T, Saga Y, Urabe M, Uchibori R, Matusbara S, Fujiwara H, et al. CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6. Oncol Lett 2019;17:2197–206.

20. Li H, Sheng C, Liu H, Wang S, Zhao J, Yang L, et al. Inhibition of HBV expression in HBV transgenic mice using AAV-delivered CRISPR-SaCas9. Front Immunol 2018;9:2080.

21. Jiang C, Mei M, Li B, Zou X, Wu T, Tian Y, et al. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pck9 in vivo. Cell Res 2017;27:440–3.

22. Liu Y, Qi X, Zeng Z, Wang L, Wang J, Zhang T, et al. CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. Sci Rep 2017;7:2796.

23. Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, et al. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B 2019;9:1113–44.

24. Zhang D, Luo G, Ding X, Lu C. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B 2012;2:549–61.

25. Zhang Z, Tang W. Drug metabolism in drug discovery and development. Acta Pharm Sin B 2018;8:721–32.

26. Wang X, Tang Y, Lu J, Shao Y, Qin X, Li Y, et al. Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9. Biochem Pharmacol 2016;105:80–90.

27. Yoshimi K, Kunihiro Y, Kaneko T, Nagahora H, Voigt B, Mashimo T. ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes. Nat Commun 2016;7:10431.

28. Lu J, Shao Y, Qin X, Liu D, Chen A, Li D, et al. CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research. Sci Rep 2017;7:42922.
49. Wei Y, Yang L, Zhang X, Sui D, Wang C, Wang K, et al. Generation and characterization of a CYP2C11-null rat model by using the CRISPR/Cas9 method. Drug Metab Dispos 2018; 46:525–31.
50. Lu J, Chen A, Ma X, Shang X, Zhang Y, Guo Y, et al. Generation and characterization of cytochrome P450 2J3/10 CRISPR/Cas9 knockout rat model. Drug Metab Dispos 2020;48:1129–36.
51. Liang C, Zhao J, Lu J, Zhang Y, Ma X, Shang X, et al. Development and characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 knockout rat model. Drug Metab Dispos 2019; 47:71–9.
52. Ma X, Shang X, Qin X, Lu J, Liu M, Wang X. Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease. Acta Pharm Sin B 2020;10:850–60.
53. Qin X, Lu J, Wang P, Xu P, Liu M, Wang X. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats. Biochem Pharmacol 2017;143:129–39.
54. Huanying Danjuan, Sui Wei, Liu Yuannan, et al. Effects of CYP2C11 gene knockout on the pharmacokinetics and pharmacodynamics of warfarin in rats. Xenobiotica 2019;49:1478–84.
55. Liu W, Sui D, Ye H, Ouyang Z, Wei Y. CYP2C11 played a significant role in down-regulating rat blood pressure under the challenge of a high-salt diet. PeertJ 2019;7:e6807.
56. Wang J, Gan C, Retnamana IA, Sparidans RW, Li W, Lebre MC, et al. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. Int J Pharm 2019;556:172–80.
57. Simoff I, Karlgren M, Backlund M, Lindstrom AC, Gaugaz FZ, Matsson P, et al. Complete knockout of endogenous Mdr1 (Abcb1) in MDCK cells by CRISPR-Cas9. J Pharm Sci 2016;105:1017–21.
58. Ma X, Qin X, Shang X, Liu M, Wang X. Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. Biochem Pharmacol 2019;169:113612.
59. Qin X, Wang X. Role of vitamin D receptor in the regulation of CYP3A gene expression. Acta Pharm Sin B 2019;9:1087–98.
60. Xie F, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B 2016;6:374–83.
61. Hashimoto M, Kobayashi K, Watanabe M, Kazuki Y, Takehara S, Inaba A, et al. Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J Lipid Res 2013;54:2060–8.
62. Hashimoto M, Kobayashi K, Yamazaki M, Kazuki Y, Takehara S, Oshimura M, et al. Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate. J Steroid Biochem Mol Biol 2016;163:121–8.
63. Yin J, Wang J. Renal drug transporters and their significance in drug–drug interactions. Acta Pharm Sin B 2016;6:363–73.
64. Kalioikoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693–705.
65. van de Steeg E, Stranecky V, Hartmannova H, Noskova L, Hrebicek M, Wagenaar E, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012;122:519–28.
66. Ellis JL, Bove KE, Schuetz EG, Leino D, Valencia CA, Schuetz JD, et al. Zebrafish abcb11b mutant reveals strategies to restore bile excretion impaired by bile salt export pump deficiency. Hepatology 2018;67:1531–45.
67. Akcakaya P, Bobbin ML, Guo JA, Malagon-Lopez J, Clement K, Garcia SP, et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 2018;561:416–9.
68. Lu J, Shang X, Zhong W, Xu Y, Shi R, Wang X. New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases. Acta Pharm Sin B 2020;10:91–104.
69. Jamieson KL, Endo T, Darwesh AM, Samokhvalov V, Seubert JM. Cytochrome P450-derived eicosanoids and heart function. Pharmacol Ther 2017;179:47–83.
70. Luther DC, Lee YW, Nagaraj H, Scaletti F, Rotello VM. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv 2018;15:905–13.
71. Smalley E. CRISPR mouse model boom, rat model renaissance. Nat Biotechnol 2016;34: 893–4.